Next-Generation Radiopharmaceuticals for precision medicine
At Fusion, we care for our patients, our employees and our communities.
We are a purpose-driven organization. We are rooted in science and motivated by a commitment to address unmet medical needs for cancer patients. We are a team of “Fusionites” that are united by our passion and dedication towards a shared goal: by bringing the best out of everyone’s talents, we can make transformative discoveries that will impact the lives of cancer patients and our communities.
Innovation is our difference.
We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.